Back to Awarded Treatment Trials


Awarded Trial: 03T-294

Grant ID

03T-294

Illness

Schizophrenia

Primary Drug/Intervention

Reboxetine

Primary Dosage

2mg b.i.d.

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

Olanzapine

Other Dosage

10mg

Status

Completed

Investigator

Poyurovsky

Sample Size

60

Duration of Study Period for Each Subject

8 weeks

Outcome Measurements

Body weight, body mass index, SAPS, SANS, HDRS

Results

Patients receiving olanzapine were randomized to receive adjunctive reboxetine (a selective norepinephrine re-uptake inhibitor) or placebo in an effort to prevent excessive weight gain. Patients receiving reboxetine gained less weight than the placebo group (mean = 1.3kg) but the results did not achieve statistical significance. The addition of reboxetine also did not appear to improve ratings of psychiatric symptoms.

Publication

N/A

Link

N/A

PI Name

Michael Poyurovsky

Degree

MD

Center

Rappaport Faculty of Medicine, Technion Institute of Technology

Institution

Tirat Carmel Mental Health Center

Address

9 Eshkol Street

City or Town

Tirat Carmel

State or Province

N/A

Zip or Postal Code

30200

Country

Israel

Email Address

trymichael@matat.health.gov.il